Schizophrenia
Also known as: psychosis · schizoaffective disorder
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia
American Psychiatric Association (APA) · 2020 · 3rd edition (2020)
The current APA practice guideline on schizophrenia, approved by the APA Board in December 2019 and released in 2020. It addresses assessment and treatment planning alongside evidence-based pharmacological and non-pharmacological treatment, with antipsychotic medication plus monitoring of response and adverse effects as the central treatment recommendation. Linked here via the PubMed record for the executive summary because the publisher's own pages block automated access.
Psychosis and schizophrenia in adults: prevention and management
NICE (UK) · 2014 · CG178
UK national guidance on preventing and managing psychosis and schizophrenia in adults, covering early intervention, treatment across illness phases, and ongoing care. Published February 2014 with a minor update the following month.
US vs EU key differences
- Clozapine triggers differ: NICE defines eligibility operationally as inadequate response to at least two adequate antipsychotic trials, one of them a non-clozapine second-generation drug, while the American Psychiatric Association additionally recommends clozapine when suicide risk stays substantial and suggests it when aggression persists. source
- NICE quantifies the dose of psychosocial treatment (individual CBT of at least 16 planned sessions; family intervention of at least 10 sessions over 3-12 months), whereas the US guideline grades CBT for psychosis as a recommendation and family intervention only as a suggestion, without prescribing session counts. source
- The US guideline explicitly suggests long-acting injectable antipsychotics for patients who prefer them or have a history of poor or uncertain adherence, and recommends coordinated specialty care for first-episode psychosis. source
- Version currency differs sharply: the American Psychiatric Association guideline was issued in 2020 with 24 recommendations, while NICE CG178 dates to 2014. source
What changed recently
- US2nd edition (2004) → 3rd edition (2020)2020-09-01
The third edition replaces the 2004 guideline and reframes it around graded evidence-based statements, recommending clozapine for treatment-resistant schizophrenia and where suicide risk persists despite other treatment, and suggesting it where aggression persists. It also gives long-acting injectable antipsychotics a defined role for patients who prefer them or have poor or uncertain adherence, reflecting second-generation LAI formulations unavailable in 2004.
source ↗curation confidence 90% - EUCG82 (2009) → CG1782014-01-01
CG178 updates and replaces CG82, broadening the scope from schizophrenia alone to psychosis generally, so that schizoaffective, schizophreniform and delusional disorder are covered. It restructures the recommendations so psychological intervention and antipsychotic medication are presented in parallel rather than sequentially, with CBT and family intervention offered to all patients alongside any drug treatment.
source ↗curation confidence 90%
See the full update feed for changes across every system.